UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For quarterly period ended JuneSeptember 30, 2018


[   ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the transition period from _____ to _____


Commission file number: No. 0-24368


FLEXPOINT SENSOR SYSTEMS, INC.

(Exact name of registrant as specified in its charter)


Delaware

87-0620425

 (State of incorporation)

(I.R.S.  Employer Identification No.)

     

106 West Business Park Drive, Draper, Utah  84020

(Address of principal executive offices)


801-568-5111

(Registrant’s telephone number)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes [X]   No [  ]


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes [X]   No [  ]


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,”  “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer [  ]

Non-accelerated filer [  ]

Accelerated filer [  ]

Smaller reporting company [X]

Emerging growth company [   ]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [  ]


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.

Yes [  ]  No [X]


The number of shares outstanding of the registrant’s common stock was 92,863,464 as of AugustNovember 14, 2018.



1



TABLE OF CONTENTS


PART I: FINANCIAL INFORMATION


Item 1.

Condensed Financial Statements

 

 

 

 

Condensed Consolidated Balance Sheets (Unaudited) at JuneSeptember 30, 2018 and

3

 

 

December 31, 2017

 

 

 

 

Condensed Consolidated Statements of Operations for the Three

4

 

 

and SixNine Months Ended JuneSeptember 30, 2018 and 2017 (Unaudited)

 

 

 

 

Condensed Consolidated Statements of Cash Flows for the

5

 

 

SixNine Months Ended JuneSeptember 30, 2018 and 2017 (Unaudited)

 

 

 

 

Notes to Condensed Consolidated Financial Statements (Unaudited)

6

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

1312

 

 

Item 3.

Quantitative and Qualitative Disclosure about Market Risk

1817

 

 

Item 4.

Controls and Procedures

1817


PART II: OTHER INFORMATION


Item 1.  

Legal Proceedings

18

 

 

 

Item 1A.

Risk Factors

1918

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

1918

 

 

 

Item 3.

Defaults upon Senior Securities

1918

 

 

 

Item 4

Mine Safety Disclosures

1918

 

 

 

Item 5.

Other Information

1918

 

 

 

Item 6.

Exhibits

2019

 

 

Signatures

2120





PART I - FINANCIAL INFORMATION


ITEM 1.  CONDENSED FINANCIAL STATEMENTS

The financial information set forth below with respect to our condensed consolidated financial position as of JuneSeptember 30, 2018, the condensed consolidated statements of operations for the three and sixnine months ended JuneSeptember 30, 2018 and 2017, and cash flows for the sixnine months ended JuneSeptember 30, 2018 and 2017 are unaudited. The information presented below for the condensed consolidated financial position as of December 31, 2017 was audited and reported as part of our annual filing of our Form 10-K, filed with Securities and Exchange Commission on April 17, 2018.  The results of operations for the three and sixnine months ended JuneSeptember 30, 2018 and 2017, respectively, are not necessarily indicative of results to be expected for any subsequent periods.

2





FLEXPOINT SENSORSYSTEMS, INC. AND SUBSIDIARIES

 CONDENSED CONSOLIDATED BALANCE SHEETS


 June 30,

2018 (Unaudited)

 

December 31, 2017

 September 30,

2018 (Unaudited)

 

December 31, 2017

ASSETS

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

Cash and cash equivalents

$             5,519

 

 $        12,832

$             3,062

 

 $        12,832

Accounts receivable, net of allowance for bad debts of $145,179

and $145,194

3,734

 

            47,254

18,937

 

            47,254

Deposits and prepaid expenses

14,216

 

            10,144

18,184

 

            10,144

Total Current Assets

23,469

 

          70,230

40,183

 

          70,230

Long-Term Deposits

6,550

 

              6,550

6,550

 

              6,550

Property and Equipment, net of accumulated depreciation

 

 

 

 

 

 

of $590,125 and $589,006

              7,465

 

             8,584

of $590,685 and $589,006

                6,905

 

             8,584

Patents and Proprietary Technology, net of accumulated

 

 

 

 

 

 

amortization of $942,028 and $925,790

32,017

 

           48,295

amortization of $949,958 and $925,790

24,087

 

           48,295

Goodwill

4,896,917

 

        4,896,917

4,896,917

 

        4,896,917

Total Assets

$   4,966,418

 

 $     5,030,576

$    4,974,642

 

 $     5,030,576

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

Accounts payable

 $      337,179

 

 $       227,680

 $       365,864

 

 $        227,680

Accounts payable – related party

12,127

 

-

Accrued liabilities

1,020,481

 

          958,810

1,079,200

 

          958,810

Due to related parties

60,500

 

20,000

-

 

20,000

Convertible notes payable, net of discount of $19,911 and $72,986

960,089

 

         807,014

Convertible notes payable to related party, net of discount of $18,985 and $33,099

95,528

 

            81,414

Convertible notes payable, net of discount of $18,275 and $72,986

1,036,725

 

         807,014

Convertible notes payable to related party, net of discount of

$17,497 and $33,099

162,016

 

            81,414

Derivative liabilities

182,518

 

363,680

131,190

 

363,680

Total Liabilities

2,656,295

 

    2,458,598

$    2,787,122

 

   $    2,458,598

 

 

 

 

 

 

Stockholders' Equity

 

 

 

 

 

 

Preferred stock – $0.001 par value; 1,000,000 shares authorized;

 

 

 

 

 

 

no shares issued or outstanding

                  -

 

                  -

                  -

 

                  -

Common stock – $0.001 par value; 100,000,000 shares authorized;

Common stock – $0.001 par value; 100,000,000 shares authorized;

 

 

Common stock – $0.001 par value; 100,000,000 shares authorized;

 

 

92,863,464 shares and 92,863,464 shares issued and outstanding,

92,863

 

            92,863

92,863

 

            92,863

Additional paid-in capital

29,785,568

 

     29,785,568

29,785,568

 

     29,785,568

Accumulated deficit

(27,568,308)

 

    (27,306,453)

(27,690,911)

 

    (27,306,453)

Total Stockholders' Equity

2,310,123

 

        2,571,978

2,187,520

 

        2,571,978

Total Liabilities and Stockholders' Equity

$    4,966,418

 

 $     5,030,576

$    4,974,642

 

 $     5,030,576



The accompanying notes are an integral part of these condensed consolidated financial statements



3






FLEXPOINT SENSOR SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)


 

For the Three Months

 

For the Six Months

 

For the Three Months

 

For the Nine Months

 

Ended June 30,

 

Ended June 30,

 

Ended September 30,

 

Ended September 30,

 

2018

 

2017

 

2018

 

2017

 

2018

 

2017

 

2018

 

2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Design, Contract and Testing Revenue

 

$          51,158

 

$        154,636

 

$        130,422

 

$        215,701

 

$          72,208

 

$        40,622

 

$        202,630

 

$        256,323

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Costs and Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of patents and proprietary

 

 

 

 

 

 

 

 

Amortization of patents and

 

 

 

 

 

 

 

 

proprietary technology

 

           8,139

 

 ��         12,110

 

           16,278

 

           30,533

 

           7,930

 

           9,154

 

           24,208

 

           39,687

Cost of revenue

 

    5,672

 

    30,892

 

23,913

 

34,641

 

    11,102

 

    8,503

 

35,015

 

43,144

Administrative and marketing expense

 

         117,278

 

         189,738

 

         233,636

 

         354,851

 

         112,141

 

         160,769

 

        345,777

 

         515,620

Research and development expense

 

           81,928

 

           85,143

 

         163,805

 

         164,509

 

           73,873

 

           79,975

 

         237,678

 

         244,484

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Operating Costs and Expenses

 

         213,017

 

         317,883

 

         437,632

 

         584,534

 

         205,046

 

         258,401

 

         642,678

 

         842,935

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Operating Loss

 

(161,859)

 

(163,247)

 

(307,210)

 

(368,833)

 

(132,838)

 

(217,779)

 

(440,048)

 

(586,612)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income and Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

        (78,876)

 

        (63,730)

 

   (157,508)

 

     (165,340)

 

        (78,383)

 

        (73,197)

 

    (235,891)

 

      (238,537)

Interest income

 

11

 

11

 

23

 

23

 

12

 

12

 

35

 

35

Gain(Loss) on derivative

 

82,091

 

33,492

 

         202,840

 

            49,179

 

88,606

 

63,006

 

         291,446

 

          112,185

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Other Income (Expense)

 

        3,226

 

        (30,227)

 

        45,355

 

    (116,138)

 

        10,235

 

        (10,179)

 

        55,590

 

       (126,317)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

$     (158,633)

 

$     (193,474)

 

$     (261,855)

 

$     (484,971)

 

$     (122,603)

 

$     (227,958)

 

 

$     (384,458)

 

 

$     (712,929)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted Loss per Common Share

Basic and Diluted Loss per Common Share

$           (0.00)

 

$           (0.00)

 

$           (0.00)

 

$           (0.01)

Basic and Diluted Loss per Common Share

$           (0.00)

 

$           (0.00)

 


$           (0.00)

 


$           (0.01)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted Weighted-Average

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Shares Outstanding

 

    92,863,464

 

    78,363,464

 

    92,863,464

 

    78,363,464

 

    92,863,464

 

    78,363,464

 

    92,863,464

 

    78,363,464






 The accompanying notes are an integral part of these condensed consolidated financial statements




4





FLEXPOINT SENSOR SYSTEMS, INC. AND SUBSIDIARIES

 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


 

 

For the Six Months

For the Nine Months

Ended June 30,

Ended September 30,

2018

 

2017

2018

 

2017

Cash Flows from Operating Activities:

 

 

 

 

 

 

Net loss

$   (261,855)

 

$   (484,971)

$   (384,458)

 

$   (712,929)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Stock-based compensation expense

-

 

9,890

-

 

14,916

Amortization of patents and proprietary technology

16,278

 

30,533

24,208

 

39,687

Amortization of discount on note payable

88,867

 

3,246

129,269

 

22,049

Depreciation

1,119

 

1,120

1,679

 

1,679

Change in fair value of derivative liabilities

(202,840)

 

(49,179)

(291,446)

 

(112,185)

Interest expense recognized for derivative liabilities

-

 

63,298

-

 

63,298

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

43,535

 

(34,750)

28,332

 

(2,415)

Deposits and prepaid expenses

(4,087)

 

(20)

(8,055)

 

(2,034)

Accounts payable

           109,499

 

           13,674

           138,184

 

           40,344

Accounts payable – related parties

-

 

14,174

12,127

 

(1,420)

Accrued liabilities

            61,671

 

      214,604

            120,390

 

           336,342

Net Cash Used in Operating Activities

(147,813)

 

(218,381)

(229,770)

 

(312,668)

 

 

 

 

 

 

Cash Flows from Investing Activities:

 

 

 

 

 

 

Note receivable interest income

-

 

-

Purchase of proprietary technology

-

 

(1,650)

Net Cash Used in Investing Activities

-

 

-

-

 

(1,650)


Cash Flows from Financing Activities:

 

 

 

 

 

 

Proceeds from bank overdrafts

-

 

19,067

Proceeds from related party payable                     40,500                          -

Repayment of bank overdrafts

-

 

(14,621)

Proceeds from borrowings under convertible note payable – related party

-

 

20,000

45,000

 

47,000

Repayment of borrowings under convertible note payable – related party

-

 

(7,000)

Proceeds from borrowings under convertible note payable

100,000

 

180,000

175,000

 

300,000

Net Cash Provided by Financing Activities

140,500

 

219,667

220,000

 

325,379

 

 

 

 

 

 

Net Change in Cash and Cash Equivalents

(7,313)

 

686

(9,770)

 

11,061

Cash and Cash Equivalents at Beginning of Period

12,832

 

-

12,832

 

-

Cash and Cash Equivalents at End of Period

5,519

 

686

3,062

 

11,061 

 

 

 

 

 

 

Supplemental Cash Flow Information:

 

 

 

 

 

 

Cash paid for income taxes

$                   -- 

 

$                -- 

$                   -- 

 

$                -- 

Cash paid for interest

$                   -- 

 

 $                -- 

$                   -- 

 

 $                -- 

Supplemental Disclosure on Noncash Investing and Financing Activities

 

 

 

 

 

 

Recognition of discounts on convertible notes payable

$           21,678

 

$         25,928

$            58,956

 

$        99,221

Assumption of liabilities by related parties

$                   -- 

 

   $        54,513

Conversion of due to related party to convertible note

$            20,000

 

$                --







The accompanying notes are an integral part of these condensed consolidated financial statements



5





FLEXPOINT SENSOR SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)


NOTE 1SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES


Condensed Consolidated Interim Financial Statements – The accompanying unaudited condensed consolidated financial statements include the accounts of Flexpoint Sensor Systems, Inc. and its subsidiaries (the “Company”). These financial statements are condensed and, therefore, do not include all disclosures normally required by accounting principles generally accepted in the United States of America. Therefore, these statements should be read in conjunction with the most recent annual consolidated financial statements of Flexpoint Sensor Systems, Inc. and subsidiaries for the year ended December 31, 2017 included in the Company’s Form 10-K filed with the Securities and Exchange Commission on April 17, 2018. In particular, the Company’s significant accounting principles were presented as Note 1 to the Consolidated Financial Statements in that report. In the opinion of management, all adjustments necessary for a fair presentation have been included in the accompanying condensed consolidated financial statements and consist of only normal recurring adjustments. The results of operations presented in the accompanying condensed consolidated financial statements are not necessarily indicative of the results that may be expected for the full year ending December 31, 2018.


Nature of Operations – Flexpoint Sensor Systems, Inc. (the Company) is located in Draper, Utah. The Company’s activities to date have included acquiring equipment and enhancing technology, obtaining financing, limited production and seeking long-term manufacturing contracts. The Company’s operations are in designing, engineering, manufacturing and selling sensor technology and equipment using flexible potentiometer technology. Through June 30, 2018 the Company continued to manufacture products and sensors to fill customer orders and provide engineering and design work.


Use of Estimates – The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods.  Actual results could differ from those estimates.


Cash and Cash Equivalents – Cash and cash equivalents are considered to be cash and highly liquid securities with original maturities of three months or less.


Fair Value MeasurementsThe fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk, including the party’s own credit risk.

Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value



6





hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

The carrying value of the Company’s cash, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.

The Company has classified the inputs used in valuing its derivative liabilities as Level 3 inputs. The Company valued its derivatives using the binomial lattice model. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed below are that of volatility and market price of the underlying common stock of the Company.


Accounts Receivable – Trade accounts receivable are recorded at the time product is shipped or services are provided including any shipping and handling fees. Contracts associated with design and development engineering generally require a deposit of 50% of the quoted price prior to the commencement of work. The deposit is considered deferred income until the entire project is completed and accepted by the customer, at which time the entire contract price is billed to the customer and the deposit applied. The Company has established an allowance for bad debts based on a historical experience and an analysis of risk associated with the account balances.  The balance in the allowance account was $145,179 and $145,194 in the periods ended June 30, 2018 and December 31, 2017, respectively.  


Property and Equipment Property and equipment are stated at cost.  Additions and major improvements are capitalized while maintenance and repairs are charged to operations.  Upon trade-in, sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is recognized. Depreciation is computed using the straight-line method and is recognized over the estimated useful lives of the property and equipment, which range from three to ten years.


Valuation of Long-lived Assets – The carrying values of the Company’s long-lived assets are reviewed for impairment annually and whenever events or changes in circumstances indicate that they may not be recoverable. When projections indicate that the carrying value of the long-lived asset is not recoverable, the carrying value is reduced by the estimated excess of the carrying value over the projected discounted cash flows. Under similar analysis no impairment charge was taken during the period ended June 30, 2018 and during the period ended December 31, 2017.  Impairment tests will be conducted on an annual basis and, should they indicate a carrying value in excess of fair value, additional impairment charges may be required.


Intangible Assets – Costs to obtain or develop patents are capitalized and amortized over the remaining life of the patents, and technology rights are amortized over their estimated useful lives. The Company currently has the right to several patents and proprietary technology.  Patents and technology are amortized from the date the Company acquires or is awarded the patent or technology right, over their estimated useful lives, which range from 5 to 15 years.  An impairment charge is recognized if the carrying amount is not recoverable and the carrying amount exceeds the fair value of the intangible assets as determined by projected discounted net future cash flows.  Under similar analysis there was no impairment charge taken during the period ended June 30, 2018 and during year ended December 31, 2017.


Research and Development – Research and development costs are recognized as an expense during the period incurred, which is until the conceptual formulation, design, and testing of a process is completed and the process has been determined to be commercially viable.


Goodwill– Goodwill represents the excess of the Company’s reorganization value over the fair value of net assets of the Company upon emergence from bankruptcy. Goodwill is not amortized, but is tested for impairment annually, or at interim periods when a triggering event occurs using a fair value approach. According to Accounting Standards Codification (or “ASC”) 350-20 Intangibles – Goodwill and Other, a fair-value-based test is applied at the overall Company level. The test compares the fair value of the Company to the carrying value of its net assets. This test requires various judgments and estimates. The fair value of the Company is allocated to the Company’s assets and liabilities based upon their fair values with the excess fair value allocated to goodwill. An impairment of goodwill is measured as the excess of the carrying amount of goodwill over the determined fair value.


Revenue Recognition – The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict



7





the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled to exchange for those goods or services. The Company only applies the five step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods and services transferred to the customer.  The following five steps are applied to achieve that core principle:


Step 1.  Identify the contract with the customer

Step 2.  Identify the performance obligations in the contract

Step 3.  Determine the transaction price

Step 4.  Allocate the transaction price to the performance obligations in the contract

Step 5.  Recognize revenue when the Company satisfied a performance obligation


Stock-Based Compensation – The Company recognizes the cost of employee services received in exchange for stock options and awards of equity instruments based on the grant-date fair value of such options and awards, over the period they vest.   All share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense in operations over the requisite service period. For the periods ended JuneSeptember 30, 2018 and 2017, the Company recognized expense for stock-based compensation of $0 and $9,890, respectively.


Basic and Diluted Loss Per Share – Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period.  Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the period. At JuneSeptember 30, 2018 there were outstanding common share equivalents (options and convertible notes payable) which amounted to 21,266,61924,162,571 of common stock. These common share equivalents were not included in the computation of diluted loss per share as their effect would have been anti-dilutive, thereby decreasing loss per common share.


Concentrations and Credit Risk - The Company has a few major customers who represent a significant portion of revenue, accounts receivable and notes receivable.  During the six month period ended June 30, 2018, two customers represented 50% of sales and represented 5% of accounts receivable.  The Company has a strong ongoing relationship with this customer with scheduled delivery extending through the year and does not believe this concentration poses a significant risk, as their products are based entirely on the Company’s technologies.  


Income Taxes - The Company accounts for income taxes in accordance with Statement of Financial Accounting Standards Board Accounting Codification (ASC) 740: Income Taxes.  Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which the differences are expected to reverse.  Deferred tax assets will be reflected on the balance sheet when it is determined that it is more likely than not that the asset will be realized.


Recent Accounting Pronouncements – Public law No. 115-97, known as the Tax Cuts and Jobs Act “the “Tax Act”). Enacted on December 22, 2017, reduced the U.S. federal corporate tax rate from 35% to 21% effective January 1, 2018.  Also on December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act.  SAB 118 provides a measurement period of up to one year from the enactment date to complete the accounting.  Any adjustments during this measurement period will be included in net earnings from continuing operations as an adjustment to income tax expense in the reporting period when such adjustments are determined.  As the Company has net operating loss carryforwards which will offset tax liability for the coming year or years, no adjustments for the effect of the income tax rate change is reflected in our financial statements.




6





In February 2018, the Financial Standards Accounting Board (“FASB”) issued Accounting Statement Update No. 2018-02, “Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.”  This ASU allows a reclassification from accumulated other comprehensive income (“AOCI”) to retained earnings for certain income tax effects stranded in AOCI as a result of the Tax Act.  The reclassification eliminates the stranded tax effects resulting from the Tax Act and is intended to improve the usefulness of information reported to financial statement users.  ASU No. 2018-02 is effective for reporting periods beginning on January 1, 2019; early adoption is permitted. The Company does not currently have amounts to be reclassified under this and therefore believes it will not have an impact on its financial statements and statements of operations.


In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718),” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity of financial reporting for non-employee share-based payments. Currently, the accounting requirements for non-employee and employee share-based payments are significantly different. ASU 2018-07 expands the scope of Topic 718, which currently only includes share-based payments to employees, to include share-based payments to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, “Equity — Equity-Based Payments to Nonemployees”. The amendments to ASU 2018 - 07 are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company’s adoption date of ASU No. 2014-09, (Topic 606), “Revenue from Contracts with Customers”. The Company is currently evaluating ASU 2018-07 and its impact on its condensed consolidated financial statements or disclosures.


In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule is effective on November 5, 2018. The Company is in the process of evaluating the impact of the final rule on its consolidated financial statements.


The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its consolidated results of operation, financial position and cash flows.  Based on that review, the Company believes that none of these pronouncements will have a significant effect on its current or future earnings or operations.



8






NOTE 2 – GOING CONCERN


The Company continues to accumulate significant operating losses and has an accumulated deficit of $27,568,308$27,690,911 at JuneSeptember 30, 2018.  These factors raise substantial doubt about the Company’s ability to continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of these uncertainties.


Management is seeking additional funding to provide operating capital for its operations until such time as revenues are sufficient to sustain our level of operations.  However, there is no assurance that additional funding will be available on acceptable terms, if at all.


NOTE 3 – DERIVATIVE INSTRUMENTS


The derivative liability as of JuneSeptember 30, 2018, in the amount of $182,518$131,190 has a Level 3 fair value classification.

 

The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of JuneSeptember 30, 2018 and December 31, 2017:

 

7


 

 

 

 

Total

 

Balance, December 31, 2016

 

 

 

 

76,295

 

Recognition of derivative liabilities upon initial valuation

 

 

 

 

226,651

 

Change in fair value of derivative liabilities

 

 

 

 

60,734

 

Conversions of derivative liabilities into equity instruments

 

 

 

 

-

 

Balance, December 31, 2017

 

 

 

 

363,680

 

Recognition of derivative liabilities upon initial valuation

 

 

 

 

21,67858,956

 

Change in fair value of derivative liabilities

 

 

 

 

(202,840)(291,446)

 

Conversions of derivative liabilities into equity instruments

 

 

 

 

-

 

Balance, JuneSeptember 30, 2018

 

 

 

 

182,518131,190

 

 

During the year ended December 31, 2017 and the period ended September 30, 2018, the Company issued convertible promissory notes which are convertible into common stock. Due to the Company’s lack of authorized shares necessary to settle all convertible instruments, in accordance with ASC 815-40-25, the Company determined that the conversion features related to these notes are derivative instruments since we do not have control to increase the number of authorized shares to settle all convertible instruments.  The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of debenture and to fair value as of each subsequent reporting date.

At September 30, 2018, the Company marked to market the fair value of the derivatives and determined a fair value of $131,190. The Company recorded a gain from change in fair value of derivatives of $291,446 for the nine month period ended September 30, 2018.  The fair value of the embedded derivatives was determined using binomial lattice model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 100.37% to 115.15%, (3) weighted average risk-free interest rate of 2.19% to 2.36% (4) expected life of 0.25 to 1.25 years, and (5) the quoted market price of the Company’s common stock at each valuation date.


In accordance ASC 840-15-25, the Company has implemented a sequencing policy with respect to all outstanding convertible instruments. The Company evaluates its contracts based upon earliest issuance date.


As of September 30, 2018, liabilities measured at fair value on a recurring basis are summarized as follows:


 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

Derivative Liabilities

 

 

-

 

 

 

-

 

 

 

131,190

 

 

 

131,190

Total

 

$

-

 

 

$

-

 

 

$

131,190

 

 

$

131,190


Convertible Notes Payable


At December 31, 2017 there were notes outstanding with principal balances which total $880,000. Of the notes, $840,000 are convertible notes bearing a 10% annual rate of interest (with a 15% default rate) and are convertible into shares of common stock at the rate of $0.06 to $0.07 per share.  The remaining $40,000 is a convertible note entered into on August 8, 2011 with a former Company Director.  That note was due on December 31, 2015, is currently in default, and therefore bears a default interest rate of 10%.  


On January 31, 2018, the Company entered into a convertible note for up to $100,000 from a third party.  The note was due on July 31, 2018, is currently in default, and therefore bears a default interest rate of 15%.  On February 23, April 13, and May 17, 2018 the Company drew $40,000, $30,000, and $30,000 against this note.


On June 15, 2018, the Company entered into a convertible note for up to $150,000 from a third party.  The note has an annual interest rate of 10% and is secured by the Company’s equipment.  The note has a conversion feature for restricted common shares at $0.06 per share and a maturity date of March 31, 2019.  On July 2, August 1, September 5, 2018, the Company drew $25,000, $25,000 and $25,000 against this note.


During the year ended December 31, 2017 and the period ended June 30, 2018, the Company issued convertible promissory notes which are convertible into common stock. Due to the Company’s lack of authorized shares necessary to settle all convertible instruments, in accordance with ASC 815-40-25, the Company determined that the conversion features related to these notes are derivative instruments since we do not have control to increase the number of authorized shares to settle all convertible instruments.  The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of debenture and to fair value as of each subsequent reporting date.


The Company recognizes a debt discount for the initial value of the derivative liability.  The resultant debt discount is amortized over the term of the note.  At September 30, 2018 there was $18,275 in unamortized debt discounts related to the above notes which will be expensed over future periods.




8





Convertible Note Payable Related Party


At December 31, 2017 there were notes outstanding with two directors of the Company with balances of $87,257 and $27,256, respectively.  The notes bear an 8% annual rate of interest with a 12% default rate. These notes were due as follows:  $10,000 was due November 30, 2016, $10,000 was due December 31, 2016, $30,000 was due December 31, 2017, and $64,513 is due December 31, 2018.  These notes are convertible into shares of common stock at the rate of $0.07 per share.


On August 28, 2018, the Company entered into two convertible notes with directors of the Company for $60,000 and $5,000.  These notes are due December 31, 2019  and are convertible into shares of common stock at the rate of $0.06 per share.


During the year ended 2017 and the period ended June 30, 2018, the Company issued convertible promissory notes which are convertible into common stock. Due to the Company’s lack of authorized shares necessary to settle all convertible instruments, in accordance with ASC 815-40-25, the Company determined that the conversion features related to these notes are derivative instruments since we do not have control to increase the number of authorized shares to settle all convertible instruments.  The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of debenture and to fair value as of each subsequent reporting date.


At June 30, 2018,The Company recognizes a debt discount for the Company marked to market the fairinitial value of the derivatives and determined a fair value of $182,518.derivative liability.  The Company recorded a gain from change in fair value of derivatives of $202,840 forresultant debt discount is amortized over the six month period ended June 30, 2018.  The fair valueterm of the embedded derivatives was determined using binomial lattice model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 86.12% to 94.90%, (3) weighted average risk-free interest rate of 2.11% to 2.33% (4) expected life of 0.33 to 0.75 years, and (5) the quoted market price of the Company’s common stock at each valuation date.

In accordance ASC 840-15-25, the Company has implemented a sequencing policy with respect to all outstanding convertible instruments. The Company evaluates its contracts based upon earliest issuance date.

As of Junenote.  At September 30, 2018 liabilities measured at fair value on a recurring basis are summarized as follows:


 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

Derivative Liabilities

 

 

-

 

 

 

-

 

 

 

182,518

 

 

 

182,518

Total

 

$

-

 

 

$

-

 

 

$

182,518

 

 

$

182, 518






9





Convertible Notes Payable


At December 31, 2017 there are notes outstanding with principal balances which total $880,000. Of the notes, $840,000 are convertible notes bearing a 10% annual rate of interest (with a 15% default rate) and are convertible into shares of common stock at the rate of $0.06 to $0.07 per share.  The remaining $40,000 is a convertible note entered into on August 8, 2011 with a former Company Director.  That note was due on December 31, 2015, and bears a default interest rate of 10%.


On January 31, 2018, the Company entered into a convertible note for up to $100,000 from a third party.  The note has an annual interest rate of 10% and is secured by the Company’s equipment.  The note has a conversion feature for restricted common shares at $0.07 per share and a maturity date of July 31, 2018.  On February 23, April 13 and May 17, 2018 the Company drew $40,000, $30,000, and $30,000, respectively against this note.


On June 15, 2018, the Company entered into a convertible note for up to $150,000 from a third party.  The note has an annual interest rate of 10% and is secured by the Company’s equipment.  The note has a conversion feature for restricted common shares at $0.06 per share and a maturity date of March 31, 2019.  On July 2, 2018 the Company drew $25,000 against this note.


Convertible Note Payable Related Party


At December 31, 2017 there are notes outstanding with two directors of the Company with balances of $87,257 and $27,256, respectively.  The notes bear an 8% annual rate of interest with a 12% default rate.  There are $50,000$17,497 in notesunamortized debt discounts related to the first officer that had due dates of December 31, 2016 and December 31, 2017, and onabove notes which interest is being calculated at the default rate.  The remaining $37,257 and $27,256 notes have due dates of December 31, 2018. All of the convertible notes issued to directors are convertible into shares of common stock at the rate of $0.07 per share.will be expensed over future periods.


NOTE 4 STOCK OPTION PLANS


On August 25, 2005, the Board of Directors of the Company approved and adopted the 2005 Stock Incentive Plan (the Plan). The Plan became effective upon its adoption by the Board and will continue in effect for ten years, unless terminated.  This plan was approved by the stockholders of the Company at their annual meeting of shareholders on November 22, 2005. Under the Plan, the exercise price for all options issued will not be less than the average quoted closinglosing market price of the Company’s trading common stock for the thirty day period immediately preceding the grant date plus a premium of ten percent.  The maximum aggregate number of shares that may be awarded under the planlan is 2,500,000 shares.  The Company continues to utilize the Black-Scholes option-pricing model for calculating the fair value of the options granted as defined by ASC Topic 718, which is an acceptable valuation approach under ASCSC 718. This model requires the input of subjective assumptions, including the expected price volatility of the underlying stock.


On August 24, 2015, the Board of Directors approved the issuance of options to purchase 2,185,000 shares of the Company’s common stock.  Of the total issued, 1,960,000 options were issued to replace options held by directors and employees which were to expire and 225,000 options were issued to new employees.  Of the options issued, 640,000 have an option price of $0.14 per share, 500,000 have an option price of $0.15 per share, 995,000 have an option price of $0.20 per share, and 50,000 have an option price of $0.25 per share.  Options issued as replacement shall have immediate vesting terms. Options which are not replacements shall vest over a two year four month period in equal installments on the last day of 2015, 2016 and 2017, respectively.  We relied on an exemption from the registration requirements provided by Section 4(a)(2) of the Securities Act.


Projected data related to the expected volatility and expected life of stock options is based upon historical and other information, and notably, the Company's common stock has limited trading history. Changes in these subjective assumptions can materially affect the fair value of the estimate, and therefore, the existing valuation models do not provide a precise measure of the fair value of the Company's employee stock options.  Between August 25, 2005 and December 31, 2015, the Company granted options to employees to purchase an aggregate 3,096,000 shares of common stock at exercise prices ranging from $0.14 to $2.07 per share.  The options vest over three years and expire 10 years from the date of grant.  The Company used the following assumptions in estimating the fair value of the options granted:


·

Market value at the time of issuance – Range of $0.14 to 2.07



10





·

Expected term – Range of 3.7 years to 10.0 years

·

Risk-free interest rate – Range of 1.60% to 4.93%



9





·

Dividend yield – 0%

·

Expected volatility – 200% to 424%

·

Weighted-average fair value - $0.16 to $2.07


All of the options were fully vested at December 31, 2017. As a result there was no stock-based compensation expenses recorded for the three and sixnine months ended JuneSeptember 30, 2018.  The Company recognized $-0-$0 and $9,890 in stock-based compensation expense for the three and sixnine months period ended JuneSeptember 30, 2017. There were 2,185,000 and 2,185,000 employee stock options outstanding at JuneSeptember 30, 2018 and December 31, 2017, respectively.  


A summary of all employee options outstanding and exercisable under the plan as of JuneSeptember 30, 2018, and changes during the threenine months then ended is set forth below:


Options

Shares

Weighted Average Exercise Price

Weighted Average Remaining Contractual  Life (Years)

Aggregate Intrinsic Value

Shares

Weighted Average Exercise Price

Weighted Average Remaining Contractual  Life (Years)

Aggregate Intrinsic Value

 

 

 

 

 

 

 

 

Outstanding at the beginning of period

         2,185,000

 $                0.17

             7.65

$              --   

         2,185,000

 $                0.17

             7.65

 $              --

Granted

--   

--

                   --   

                 --   

--

--

                   --

                 --

Expired

                     --   

                             --

                   --   

                 --   

                     --

                             --

                   --

                 --

Forfeited

--   

--

                   --   

                --   

--

--

                   --

                --

Outstanding at the end of Period

       2,185,000

 $                 0.17

             7.16

$               --   

       2,185,000

 $                 0.17

             6.91

$               --

Exercisable at the end of Period

2,185,000

 $                 0.17

             7.16

$               --   

2,185,000

 $                 0.17

             6.91

    $               --


NOTE 5 – CAPITAL STOCK


Preferred Stock – There are 1,000,000 shares of preferred stock with a par value of $0.001 per share authorized.  At JuneSeptember 30, 2018 and December 31, 2017, there were no shares of preferred stock issued or outstanding.


Common Stock – There are 100,000,000 shares of common stock with a par value of $0.001 per share authorized.  No shares of stock were issued during the sixnine months ended JuneSeptember 30, 2018.  


NOTE 6 – COMMITMENTS AND CONTINGENCIES


The Company currently occupies approximately 11,639 square feet of office and manufacturing space from American Covers, Inc., dba Handstands. In 2014 the Company extended the operating lease agreement for its manufacturing facility in Draper, Utah. Under the terms of a three year lease extension effective January 1, 2015, the monthly rent remained at $8,950 per month for 2015, increased to $9,300 per month for 2016 and to $9,600 per month for 2017. The lease further provides that on the expiration of the lease on December 31, 2017, the lease becomes a month-to-month lease at a rate of the current monthly lease rate ($9,600), plus an increase of 10%, (now $10,560), with a 10% increase on the anniversary date of each succeeding year. The building is located in a business park in Draper, Utah which consists primarily of high tech manufacturing firms and it is located adjacent to Utah’s main interstate highway.


NOTE 7 – RELATED PARTY TRANSACTIONS


At June 30, 2018 and December 31, 2017, the Company had amounts of $60,500 and $20,000 payabledue to its Chief Executive Officer for funds loaned to the Company to pay foroff various operating expenses of the business.  These funds are non-interestThe amount owed at December 31, 2017, was converted to notes payable, bearing unsecured, andinterest at the rate of 8% per annum with a due upon demand.date of December 31, 2019.


At June 30, 2018 and December 31, 2017, the Company had outstanding notes payable to an officer in the amount of $87,257 and an outstanding note payable to a director in the amount of $27,256. On August 28, 2018, additional notes payable in the amounts of $60,000 and $5,000, respectively, were issued to directors of the Company.  See Notenote 3.






1110





NOTE 8 – SUBSEQUENT EVENTS


On JulyOctober 2, 2018 the Company drew an additional $25,000 against the $150,000 line of credit dated June 15, 2018 provided by a third party.


On October 18, 2018, the Company announced it had signed a five year manufacturing and supply agreement with a medical device company for a medicine dispensing product.  It is anticipated that full production under this agreement will commence during the first quarter of 2019.


In accordance with ASC 855-10 management reviewed all material events through the date of this report.  There are no material subsequent events to report other than those disclosed above.




1211





In this quarterly report references to “Flexpoint", "the Company," “we,” “us,” and “our” refer to Flexpoint Sensor Systems, Inc. and its subsidiaries.


FORWARD LOOKING STATEMENTS


The U.S. Securities and Exchange Commission (“SEC”) encourages reporting companies to disclose forward-looking information so that investors can better understand future prospects and make informed investment decisions.  This report contains these types of statements. Words such as “may,” “expect,” “believe,” “anticipate,” “estimate,” “project,” or “continue” or comparable terminology used in connection with any discussion of future operating results or financial performance identify forward-looking statements.  You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report.  All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.



ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


EXECUTIVE OVERVIEW


Flexpoint Sensor Systems, Inc. (“Flexpoint”, or “Company”), is principally engaged in designing, engineering and manufacturing bend sensor technology and products using its patented Bend Sensor® technology, a flexible potentiometer technology.  We continue to make further improvements to our technologies, manufacturing and developing fully integrated devices and related products that we have been marketing and selling to a variety of companies in diverse industries. We are negotiating and signing agreements, purchase orders and contracts that have provided some revenues and have proven that our sensors are more durable, adaptable and cost effective than any other product currently on the market.  


The Company owns five patents, including patents on specific devices that use the Bend Sensor® and we have exclusive rights through licensing agreements to other patents and devices.  We are continuing to develop and enhance our intellectual properties that will result in additional patents being filed. The Company currently manufactures, and has jointly developed, twenty-five products that are being sold and supplied to current customers and we continue to receive orders for custom prototype sensors as well as our standard sensors.  We are continuing to develop and enhance our intellectual properties that will result in additional patents being filed.


During 2018 we will focushave focused our marketing efforts on a number of larger domestic and international companies that have applications which have the potential to greatly increase the volume of sensors we are currently manufacturing. As of the date of this report, the Company had at least sixteen global commercial partners covering a variety of different products.  In coordination with its partners, the Company introduced at least eight new products.  Management believes this growth in sales channels will allow the Company to grow at an increasingly accelerated rate over the next several quarters.  


On October 18, 2018, the Company announced it had signed a five year manufacturing and supply agreement with Counted LLC.  Counted LLC conceived of a medication delivery monitoring system and dispensing monitoring system. Flexpoint designed and produced the monitoring system with Flexpoint features, Flexpoint technology and Flexpoint designed electronics to track and report the dispensing of medications in real time.  This information has the potential to be transmitted to physicians, pharmacists and governmental agencies.  Prototypes have been built and successfully tested and it is expected that additional production and testing will continue throughout the remainder of the year with production increasing in 2019.     


The Company has completed delivery of two different products to Haemoband, Ltd. and continues to work with them toward the completion of their testing program for product launch.


The Company continues to develop relationships in a number of application fields.  We have a collaborative working arrangementrelationship for the production of sensors for glove based IR/VR applications with 11 HealthManus VR and Technologies Inc. to develop next generation products in the medical industry.others. Flexpoint has also established relationships with several other medical IoT vendors.  These include companies like 11 Health, Neofect, Gloreha and YouReHab; all with a focus on medical rehabilitation with a different approach.  Products from these companies



12





range from gloves to prosthetics to virtual reality, all with the intention of improving medical health or medical rehab.  


In addition to the sale of our products and engineering and design services, we also may consider generating revenues through licensing our unique technology for field of use or territory. We will attempt to negotiate each license agreement to contain a provision for either first right of refusal to manufacture, or royalty provisions for specific products or applications. We have continued to concentrate our marketing efforts on sensors and electronics which we consider to be quick-to-market production orders, and on engineering services that have generated limited, but immediate, revenues that have provided cash flow and name recognition. We have also continued our marketing efforts in the automotive industry. Due to the size and the numerous regulations inherent in the automotive industry, it requires a significantly longer time to develop and acquire approvals for new technologies.  However, as there are



13





high volumes associated within the automotive industry, we anticipate that this industry will potentially generate significant long-term revenue streams.  We also have a strategic relationship with HTK Safety to begin offering an integrated safety system utilizing the Bend Sensor® technology.


We continue to work with Tier 1 automotive suppliers on a variety of products that are in various stages of development and implementation. Both the medical and automotive industries have undergone significant changes over the past several years. This changing environment has created delays in the implementation of the automotive and medical devices and therefore, over the past several years, we have focused our limited resources and marketing efforts on sensors and products that, in the aggregate, will generate a smaller dollar volume than those anticipated from our medical or automotive devices, but have a quicker pathway to market and have generated needed limited, but immediate, cash flow while providing additional name and product recognition that we believe will provide long term benefits. Based upon the current interest in our sensors from both the automotive and medical industries, we anticipate that over the next twelve months, we will begin producing larger repeatable volumes of sensors and devices in these focus industries.


LIQUIDITY AND CAPITAL RESOURCES


Currently our revenue is primarily from design contract, testing and limited production services for products, prototypes and samples, and is not to a level to support our operations.  However, we believe, based upon current orders and projected orders over the next twelve months, that we could be producing sensors under long-term contracts that will help support our existing operations and potential future growth. Management recognizes such contracts usually go through a long negotiation process and there can be no guarantee that we will be successful in our negotiations or that such contracts will be sufficient to support our current operations in the near future.


For the past twelve months we have relied on the proceeds of convertible loans from existing shareholders and private placements of our common stock.  During 2017 and the first sixnine months of 2018, the Company secured financing to fund its operations by issuing additional convertible notes to Capital Communications LLC, a third party, and our officers, the balances of which were $940,000$1,243,514 as of JuneSeptember 30, 2018. The notes have an annual interest rate of 8% to 10% and default rates of 12% to 15%, have various maturity dates, and are secured by the Company’s business assets.  On JulyOctober 2, 2018, the Company drew an additional $25,000 against the $150,000 Capital CommunicationsCommunications LLC line of credit.


Management believes that our current cash burn rate is approximately $75,000 per month and that proceeds from additional convertible notes and estimated revenues for engineering design and prototype products will be sufficient to fund the next twelve months of operations.  Our auditors have expressed doubt about our ability to continue as a going concern and that we may not realize significant revenue or become profitable within the next twelve months. We will require additional financing to fund our short-term cash needs. We will have to rely on additional debt financing, loans from existing shareholders and private placements of common stock for additional funding. Based upon our current purchase orders and anticipated purchase orders over the next twelve months our projected revenues by the end of 2018 are anticipated to cover our projected operating expenses, based on our current burn rate. However, we cannot assure you that we will be able to obtain short-term financing, or that sources of such financing, if any, will continue to be available, and if available, that they will be on terms favorable to us. Nor is there any guarantee that the projected volume of purchase orders will meet the volumes that we anticipate.


We also expect that in the short term we may have to continue to issue convertible notes, convertible into our common stock, to pay for services and agreements rather than use our limited cash resources; however, the common stock the Company is currently obligated to issue under current convertible notes will exceed the total number of shares authorized under itsour Articles of Incorporation.  Any additional issuance of common stock will likely be pursuant to exemptions provided by federal and state securities laws. The purchasers and manner of issuance will be



13





determined according to our financial needs and the available exemptions.  We also note that if we issue more shares of our common stock our shareholders may experience dilution in the value per share of their common stock.  


As we enter into new agreements, we must ensure that those agreements provide adequate funding for any pre-production research and development and manufacturing costs. If we are successful in establishing agreements with adequate initial funding, management believes that our operations for the long term will be funded by revenues, licensing fees and/or royalties related to these agreements. However, we have formalized only a few agreements during the past four years and there can be no assurance that the agreements will generate sufficient revenues or be profitable in the future or that a desired technological application will be successful enough to produce the volumes and profits necessary to fund our operations.  




14





FINANCIAL OBLIGATIONS AND CONTINGENT LIABILITIES


Our principal commitments at JuneSeptember 30, 2018 consisted of our operating lease of $10,560 per month, and total liabilities of $2,656,145,$2,787,122 which includes $960,089$1,198,742 of convertible notes payable, net of discounts of $19,911.$35,772. Accrued liabilities at JuneSeptember 30, 2018, were $1,020,481$1,079,200 and were related to payroll, payroll tax liabilities, accrued professional expenses, accrued insurance expense, accrued interest expense on notes and accrued paid time off.  


During the sixnine months ending JuneSeptember 30, 2018, the Company has raised an additional $100,000$220,000 in operating capital through the issuance of a short-term note.convertible notes.  The note has annotes have annual interest raterates of 8% to 10% and a default raterates of 12% to 15% annually. The note isnotes are secured by the Company’s business equipment and has ahave conversion featurefeatures for restricted common shares at $0.06 to $0.07 per share.


During the year ended 2017 and the period ended JuneSeptember 30, 2018, the Company issued convertible promissory notes which are convertible into common stock. Due to the Company’s lack of authorized shares necessary to settle all convertible instruments, we determined that the conversion features related to these notes are derivative instruments since we do not have control to increase the number of authorized shares to settle all convertible instruments.  At JuneSeptember 30, 2018, the Company determined a fair value of $182,518$131,190 for the derivative instruments. The Company recorded a gain from change in fair value of derivatives of $82,091$291,446 for the sixnine month period ended JuneSeptember 30, 2018.


The Company has a few major customers who represent a significant portion of revenue and accounts receivable.  During the sixnine months ended JuneSeptember 30, 2018, two customers represented 50%41% of sales and represented 5%13% of accounts receivable at JuneSeptember 30, 2018.  The Company has a strong ongoing relationship with this customer with scheduled delivery extending through the year and does not believe this concentration poses a significant risk, as their products are based entirely on the Company’s technologies


OFF-BALANCE SHEET ARRANGEMENTS


Other than our current operating lease, we have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.


CRITICAL ACCOUNTING ESTIMATES


The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates of particular significance in our financial statements include goodwill and the annual tests for impairment of goodwill and long-lived assets and valuing stock option compensation.  


The Company's goodwill represents the excess of its reorganization value over the fair value of the net assets upon emergence from bankruptcy. Goodwill is not amortized, therefore we test our goodwill for impairment annually or when a triggering event occur using a fair value approach. A fair value based test is applied at the overall Company level. The test compares the fair value of the Company to the carrying value of its nets assets. The test requires various judgments and estimates. During 2017 and for the sixnine months ending JuneSeptember 30, 2018, the Company recorded no impairment charge to reduce the carrying value of the goodwill to its estimated fair value. As part of the



14





impairment testing performed at December 31, 2017, the Company considered factors such as the global market volatility, variables in the economy, and the overall uncertainty in the markets which has resulted in a decline in the market price of the Company's stock price and market capitalization for a sustained period, as indicators for potential goodwill impairment.


We test long-lived assets for impairment annually or when a triggering event occurs. Impairment is indicated if undiscounted cash flows are less than the carrying value of the assets. The amount of impairment is measured using a discounted-cash-flows model considering future revenues, operating costs and risk-adjusted discount rate and other factors. The analysis compares the present value of projected net cash flows for the remaining current year and next two years against the carrying value of the long-lived assets. If the carrying values of the long-lived assets exceed the present value of the discounted projected revenues an impairment expense would be recognized in the period and the carrying value of the assets would be adjusted accordingly. Impairment tests are conducted on an annual basis and, should they indicate a carrying value in excess of fair value, a charge may be required.




15





Financial accounting standards require that recognition of the cost of employee services received in exchange for stock options and awards of equity instruments be based on the grant-date fair value of such options and awards and is recognized as an expense in operations over the period they vest. The fair value of the options we have granted is estimated at the date of grant using the Black-Scholes American option-pricing model. Option pricing models require the input of highly sensitive assumptions, including expected stock volatility. Also, our stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate.  Management believes the best input assumptions available were used to value the options and that the resulting option values are reasonable. For the sixnine month periods ended JuneSeptember 30, 2018 and 2017 we recognized $0 and $9,890, respectively, of stock-based compensation expense for our stock options and there is no additional unrecognized compensation cost related to employee stock options at the current time.


RESULTS OF OPERATIONS


The following discussions are based on the consolidated operations of Flexpoint Sensor Systems, Inc. and should be read in conjunction with our unaudited financial statements for the three and sixnine months ended JuneSeptember 30, 2018 and 2017, included in Part I, Item 1, above, and the audited financial statements included in the Company’s annual report on Form 10-K for the years ended December 31, 2017 and 2016.


THREE MONTH PERIOD ENDED JUNESEPTEMBER 30, 2018:


SUMMARY OF OPERATING RESULTS

SUMMARY OF OPERATING RESULTS

SUMMARY OF OPERATING RESULTS


Three month period ended


Three month period ended

June 30, 2018

 

June 30, 2017

September 30, 2018

 

September 30, 2017

Design, contract and testing revenue

$            51,158

 

$            154,636

$            72,208

 

$            40,622

Total operating costs and expenses

213,017

 

317,883

205,046

 

258,401

Net other income (expense)

3,226

 

(30,227)

10,235

 

(10,179)

Net loss

(158,633)

 

(193,474)

(122,603)

 

(227,958)

Basic and diluted loss per common share

(0.00)

 

(0.00)

$             (0.00)

 

$             (0.00)


For the three months ending JuneSeptember 30, 2018 revenue was $51,158, a decrease$72,208, an increase of $103,478$32,186 when compared to the same period in 2017. The decrease is attributable to the delay in projects by our clients, which has pushed back the requirement for our component parts. The majority of the revenue for this period came from development engineering, production, prototype and pre-production products. The Company continues to concentrate its marketing resources on a limited number of customers that have the greatest potential to generate the most short-term revenue while still building relationships with our larger customers. Management believes this approach has the highest potential to bring long-term commercially viable products to market and will provide sustainable cash flow to fund the Company's operations in the future. Currently, overall revenues are not sufficient to sustain our operations.  Management anticipates that revenues will increase as we continue to execute our long-term business plan and cultivate larger customer bases with our existing product offering. However, until a long-term production contract is in place there is no guarantee that our current customer base will order in sufficient volumes to sustain our operations. Therefore, management continues to work with larger companies and industries and is hopeful that in the near future we will sign a long-term licensing or manufacturing contract.




15





We recognized revenue from repeat orders from our existing customers, design contracts, and development engineering.  Revenue is recognized using the ASC 606 five step detailed in Note 1 to the financial statements. Revenue from the sale of a product is recorded at the time of shipment to the customer.  Revenue from research and development engineering contracts is recognized as the services are provided and accepted by the customer. Revenue from contracts to license technology to others is deferred until all conditions under the contract are met and then the sale is recognized as licensing royalty revenue over the remaining term of the contract.


Of the $205,046 and $258,401 total operating costs and expense for the three months ending September 30, 2018 and 2017, respectively, $73,873 and $79,975 were for direct research and development cost, respectively. For the three months ended September 30, 2018, total operating expenses decreased by $53,355 when compared to the same period in 2017, due primarily to reduced amortization charges and professional fees.  


Other income (expense) for the three month period ended September 30, 2018 was $10,235, a $20,414 increase compared to the same period in 2017.  The increase is attributable to a gain on the change in fair value of derivative liabilities of $88,606 for the three months ended September 30, 2018, compared to $63,006 recognized for the three month period ended September 30, 2017.

A net loss of $122,603 was realized for the three months ended September 30, 2018.  A net loss of $227,958 was realized for the three month period ended September 30, 2017.


NINE MONTH PERIOD ENDED SEPTEMBER 30, 2018:


SUMMARY OF OPERATING RESULTS

 


Nine month period ended

 

September 30, 2018

 

September 30, 2017

Design, contract and testing revenue

$            202,630

 

$            256,323

Total operating costs and expenses

642,678

 

842,935

Net other income (expense)

55,590

 

(126,317)

Net loss

(384,458)

 

(712,929)

Basic and diluted loss per common share

$               (0.00)

 

$               (0.01)


For the nine months ending September 30, 2018 revenue was $202,630, a decrease of $53,693 when compared to the same period in 2017. The majority of the revenue for this period came from development engineering, production, prototype and pre-production products. The Company continues to concentrate its marketing resources on a limited number of customers that have the greatest potential to generate the most short-term revenue while still building relationships with our larger customers. Management believes this approach has the highest potential to bring long-term commercially viable products to market and will provide sustainable cash flow to fund the Company's operations in the future. Currently, overall revenues are not sufficient to sustain our operations.  Management anticipates that revenues will increase as we continue to execute our long-term business plan and cultivate larger customer bases with our existing product offering. However, until a long-term production contract is in place there is no guarantee that our current customer base will order in sufficient volumes to sustain our operations. Therefore, management continues to work with larger companies and industries and is hopeful that in the near future we will sign a long-term licensing or manufacturing contract.


We received revenue from repeat orders from our existing customers for production, design contracts, and development engineering.  Revenue is recognized using the ASC 606 five step detailed in Note 1 to the financial statements.  Revenue from the sale of a product is recorded at the time of shipment to the customer.  Revenue from research and development engineering contracts is recognized as the services are provided and accepted by the customer. Revenue from contracts to license technology to others is deferred until all conditions under the contract are met and then the sale is recognized as licensing royalty revenue over the remaining term of the contract.


Of the $213,017$642,678 and $317,883$842,935 total operating costs and expense for the threenine months ending JuneSeptember 30, 2018 and 2017, respectively, $81,928$237,678 and $85,143$244,484 were for direct research and development cost, respectively. For the threenine months ended JuneSeptember 30, 2018, total operating expenses decreased by $104,866$200,257 when compared to the same period in 2017, due primarily to reduced amortization charges, a reduction in salaries and professionalrelated taxes and benefits, and reduced consulting fees.


Other income (expense) for the three month period ended June 30, 2018 was $3,226 a $33,453 increase compared to the same period in 2017.  The increase is attributable to a gain on the change in fair value of derivative liabilities.    



16





Other income for the nine month period ended September 30, 2018 was $55,590, compared to other expense of $126,317 for the same period in 2017.  The major contributor to this change was the recognition of a $291,446 gain on derivative in 2018 compared to a gain on derivative of $112,185 recognized in 2017.  

A net loss of $158,633$384,458 was realized for the threenine months ended JuneSeptember 30, 2018.  A net loss of $193,474$712,929 was realized for the threenine month period ended June 30, 2017.


SIX MONTH PERIOD ENDED JUNE 30, 2018:


SUMMARY OF OPERATING RESULTS

 

 

Six month period ended

 

June 30, 2018

 

June 30, 2017

Design, contract and testing revenue

$            130,422

 

$            215,701

Total operating costs and expenses

437,632

 

584,534

Net other income (expense)

45,355

 

(116,138)

Net loss

(261,855)

 

(484,971)

Basic and diluted loss per common share

(0.00)

 

(0.00)


For the six months ending June 30, 2018 revenue was $130,422, a decrease of $85,279 when compared to the same period in 2017. The lower sales result from delays in ordering from our clients.  The majority of the revenue for this period came from development engineering, prototype and pre-production products. The Company continues to concentrate its marketing resources on a limited number of customers that have the greatest potential to generate the most short-term revenue while still building relationships with our larger customers. Management believes this approach has the highest potential to bring long-term commercially viable products to market and will provide sustainable cash flow to fund the Company's operations in the future. Currently, overall revenues are not sufficient to sustain our operations.  Management anticipates that revenues will increase as we continue to execute our long-term business plan and cultivate larger customer bases with our existing product offering. However, until a long-term production contract is in place there is no guarantee that our current customer base will order in sufficient volumes to sustain our operations. Therefore, management continues to work with larger companies and industries and is hopeful that in the near future we will sign a long-term licensing or manufacturing contract.


We received revenue from repeat orders from our existing customers, design contracts, and development engineering.  Revenue is recognized using the ASC 606 five step detailed in Note 1 to the financial statements. Revenue from the sale of a product is recorded at the time of shipment to the customer.  Revenue from research and development engineering contracts is recognized as the services are provided and accepted by the customer. Revenue from contracts to license technology to others is deferred until all conditions under the contract are met and then the sale is recognized as licensing royalty revenue over the remaining term of the contract.


Of the $437,632 and $584,534 total operating costs and expense for the six months ending June 30, 2018 and 2017, respectively, $163,805 and $164,509 were for direct research and development cost, respectively. For the six months ended June 30, 2018, total operating expenses decreased by $146,902 when compared to the same period in 2017, due primarily to reduced amortization charges and professional fees.  


Other income (expense) for the six month period ended June 30, 2018 was $45,355, compared to other expense of $116,138 the same period in 2017.  The income in 2018 is attributable to a gain on the change in fair value of derivative liabilities.  

A net loss of $261,855 was realized for the six months ended June 30, 2018.  A net loss of $484,971 was realized for the six month period ended JuneSeptember 30, 2017.


The chart below represents a summary of our condensed consolidated balance sheets at JuneSeptember 30, 2018 and December 31, 2017.

SUMMARY OF BALANCE SHEET INFORMATION

 

 

 

 

 

June 30, 2018

 

December 31, 2017

Cash and cash equivalents

$                    5,519

 

$                12,832

Total current assets

23,469

 

70,230

Total assets

            4,966,418

 

            5,030,576

Total liabilities

              2,656,295

 

              2,458,598

Deficit accumulated

         (27,568,308)

 

         (27,306,453)

Total stockholder’s equity

 $       2,310,123

 

 $       2,571,978

17



SUMMARY OF BALANCE SHEET INFORMATION

 

 

 

 

 

September 30, 2018

 

December 31, 2017

Cash and cash equivalents

$             3,062  

 

$            12,832  

Total current assets

   40,183  

 

70,230  

Total assets

         4,974,642  

 

            5,030,576  

Total liabilities

              2,786,972  

 

              2,458,598  

Deficit accumulated

         (27,690,911)

 

         (27,306,453)

Total stockholder’s equity

 $       2,187,520  

 

 $       2,571,978  


Cash and cash equivalents decreased by $7,313$9,770 at JuneSeptember 30, 2018 compared to December 31, 2017. The decrease in cash is due to the timing of payment of expenses, collection of accounts receivable and proceeds from borrowings. Our non-current assets decreased at JuneSeptember 30, 2018 due to the amortization of long-lived assets.


Total liabilities increased by $197,697$328,524 at JuneSeptember 30, 2018.  The increase was due primarily to the funding of operations through the issuance ofincreases in convertible notes payable, the accrued interest related to those notes, and accruals for investor relationsother accounts payable and insurance expenses.accrued liabilities offset in part by a decrease in the derivative liability.


INFLATION


We do not expect the impact of inflation on our operations to be significant for the next twelve months.



ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK


Not applicable to smaller reporting companies.



ITEM 4.  CONTROLS AND PROCEDURES


(a)

Disclosure Controls and Procedures


As of the end of the period covered by this quarterly report we carried out an evaluation of the effectiveness of our disclosure controls and procedures under the supervision and with the participation of our Chief Executive Officer, who also serves as our Principal Financial Officer.  Our controls and procedures are designed to allow information required to be disclosed in our reports to be recorded, processed, summarized and reported within the specified periods, and accumulated and communicated to management to allow for timely decisions regarding required disclosure of material information.  Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives.  Based upon the evaluation, our Chief Executive Officer concluded that our disclosure controls and procedures were not effective at that reasonable assurance level as of the end of the period JuneSeptember 30, 2018.  


The material weaknesses relate to the limited number of persons responsible for the recording and reporting of financial information, the lack of separation of financial reporting duties, and the limited size of our management team in general. We are in the process of evaluating methods of improving our internal control over financial reporting, including the possible addition of financial reporting staff and the increased separation of financial reporting responsibility, and intend to implement such steps as are necessary and possible to correct these material weaknesses.



17






(b)

Changes in Internal Control over Financial Reporting


There have been no changes in internal control over financial reporting during the first sixnine months of 2018 that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.



PART II - OTHER INFORMATION



ITEM 1. LEGAL PROCEEDINGS


None.








18





ITEM 1A.  RISK FACTORS


We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this Item.



ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS


The Company has not issued any securities since the year ended December 31, 2017.



ITEM 3.  DEFAULTS UPON SENIOR SECURITIES


None.



ITEM 4.  MINE SAFETY DISCLOSURES


Not applicable.



ITEM 5.  OTHER INFORMATION


None.Flexpoint Sensor Systems, Inc. intends to conduct an annual shareholders’ meeting on Friday, December 28, 2018. The rules of the SEC provide that shareholder proposals may be considered for inclusion in the proxy materials for such an annual meeting under certain circumstances.  Our bylaws provide that any qualified shareholder proposals for an annual meeting must be made in writing and delivered to us or mailed and received at our principal executive offices not less than 50 days and not more than 80 days prior to that meeting.  However, if we provide you with less than 60 days’ notice (or public disclosure) of the meeting, shareholder proposals will be deemed timely if they are received not more than the 10th day following the date the notice was mailed or the public disclosure was made. Accordingly, shareholders’ proposals for the December 28, 2018 meeting must be received no later than the10th day following the date of the filing of this Form 10-Q (public disclosure), which is November 24, 2018.



Any such proposals need to be accompanied by specific information regarding:

$

a brief description of the business desired to be brought before the meeting and the reasons for conducting such business at the meeting;

$

the name and address of the shareholder proposing the business;

$

the class and number of shares owned by the shareholder; and

$

any material interest the shareholder has is such business.



[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]Under Rule 14a-8 promulgated under the Exchange Act, in order to be eligible to submit a proposal, you must be a shareholder of record and have continuously held at least $2,000 in market value, or 1%, of the Company’s



1918





securities entitled to be voted on the proposal at the meeting for at least one year by the date you submit the proposal. You must continue to hold those securities through the date of the meeting.


Based upon these factors, shareholders’ proposals for the December 28, 2018 meeting must be received no later than the10th day following the date this Form 10-Q is filed, which is November 24, 2018.


Shareholder Relations

Flexpoint Sensor Systems, Inc.

106 West Business Park Drive

Draper, Utah  84020



ITEM 6. EXHIBITS


Part I Exhibits


No.

Description

31.1

Certification of Clark M. Mower pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Clark M. Mower pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley



Part II Exhibits


No.

Description

3.1

Certificate of Incorporation of Flexpoint Sensor, as amended (Incorporated by reference to exhibit 3.1 for Form 10-QSB, filed August 4, 2006)

3.2

Bylaws of Flexpoint Sensor, as amended (Incorporated by reference to exhibit 3.4 of Form 10-QSB, filed May 3, 2004)

10.1

Addendum to Lease Agreement between Flexpoint Sensor and Handstands, dated January 1, 2015.  (Incorporated by reference to exhibit 10.3 of Form 10-K, filed April 14, 2016)

101.INS

XBRL Instance Document

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Label Linkbase Document

101.PRE

XBRL Taxonomy Presentation Linkbase Document      





2019





SIGNATURES


In accordance with the requirements of the ExchangeExchange Act, the registrant caused this report to be signed on its behalf by the undersigned, who is duly authorized.


FLEXPOINT SENSOR SYSTEMS, INC.


Date:   AugustNovember 14, 2018


/s/ Clark M. Mower

Clark M. Mower

President, Chief Executive Officer and Director,

Principal Financial Officer



2120